Videos

Thomas Powles, MD, MBBS, MRCP, discusses the mechanism of action of enfortumab vedotin-ejfv and its use in treating locally advanced or metastatic urothelial carcinoma.

Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.

Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.

Matthew A. Powell, MD, discusses the methods and design of the randomized, double-blind, phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial in endometrial cancer.

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.

Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.

Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.

Federico Albrecht, MD, discusses the standard practice on testing for a patient with small cell lung cancer at Miami Cancer Institute.

Neeraj Agarwal, MD, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium.

Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.

Virginia Kaklamani, MD, DSc, explains that in second-line treatment of metastatic HR+/HER2- breast cancer after CDK4/6 inhibitors, biomarker testing guides the choice between therapies based on the safety and resistance mutation profiles.

Virginia Kaklamani, MD, DSc, reviews the presented case of a postmenopausal patient with breast cancer who develops metastases after adjuvant endocrine therapy ends, and explains that later treatment selection is difficult because of endocrine resistance and mutations causing more aggressive disease.

Practical insights for the management of patients with NDMM.

Summary of findings presented at the 2023 ASH meeting from this phase 2 trial using daratumumab, bortezomib, thalidomide and dexamethasone with tandem autologous stem cell transplant in high risk newly diagnosed multiple myeloma patients.

Review of the final analysis of data from the MASTER clinical trial assessing daratumumab plus carfilzomib, lenalidomide and dexamethasone.

Overview of findings from this phase 3 study evaluating isatuximab added to carfilzomib, lenalidomide and dexamethasone.

Review of the key primary outcome data from this trial of subcutaneous daratumumab with bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant eligible multiple myeloma patients.

Discussion of the final data analysis comparing daratumumab plus lenalidomide, bortezomib and dexamethasone to lenalidomide, bortezomib and dexamethasone alone.

Brea C. Lipe, MD closes this series highlighting the vast landscape of effective treatments and those on the horizon.

A review of the recent findings from this clinical trial examining lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplant for newly diagnosed multiple myeloma.

Brea C. Lipe, MD reflects on how the PERSEUS trial results may affect future treatment approaches.

Brea C. Lipe, MD explains common grade 3 and grade 4 adverse events observed in the PERSEUS trial.

Dipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.

Riccardo Lencioni, MD, discusses how the new protocol from the phase 3 EMERALD-1 trial may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma.

Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.

Marcia S. Brose, MD, PhD, discusses treatment sequencing practices and offers advice for community oncologists treating patients with RAI-R-DTC.

Focusing on lenvatinib, an expert on RAI-R-DTC discusses data on real-world treatment patterns and clinical outcomes and gives an overview of papers on age and dose.

Marcia S. Brose, MD, PhD, discusses her experience with lenvatinib as a treatment for patients with RAI-R-DTC.

An expert on radioiodine-refractory differentiated thyroid cancer outlines factors to consider when selecting appropriate treatments for patients.